ArticleNagoya journal of medical science2023

T cell receptor-engineered T cells derived from target human leukocyte antigen-DPB1-specific T cell can be a potential tool for therapy against leukemia relapse following allogeneic hematopoietic cell transplantation.

Naoya Katsuyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.